Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease.
Mansour Abdullah AlghamdiLaith Naser Al-EitanRami AlkhatibAhmad Al-AssiAyah AlmasriHanan A AljamalHatem AmanRame H KhasawnehPublished in: International journal of general medicine (2021)
The current study could help in understanding the role of genetic variability in warfarin dosing and matching patients to different treatment options. Clinical applications of these findings for warfarin treatment may also contribute to improving the efficacy and safety of warfarin treatment in Jordanian patients with cardiovascular disease.
Keyphrases
- cardiovascular disease
- atrial fibrillation
- venous thromboembolism
- direct oral anticoagulants
- end stage renal disease
- oral anticoagulants
- type diabetes
- genome wide
- newly diagnosed
- chronic kidney disease
- copy number
- ejection fraction
- gene expression
- transcription factor
- metabolic syndrome
- peritoneal dialysis
- patient reported outcomes
- combination therapy
- genome wide identification